Canadian Study Finds Cannabis Use Disorder Associated with Higher Risk of Heart Disease

PainRelief.com Interview with:
Anees Bahji, BSc(H), MD, CISAM, CCSAM, DABPN, FRCPC (pronouns: he/him/his)
Clinical Assistant Professor, Department of Psychiatry, University of Calgary
Ph.D. Student, Department of Community Health Sciences, University of Calgary
Addiction, Concurrent Disorder, and General Psychiatry
Opioid Dependency Program, Sheldon M. Chumir Centre
Rapid Access to Addiction Medicine Service, Calgary
Adult Addiction Centre, 6th Floor, Foothills Medical Centre

PainRelief.com: What is the background for this study?

Response: The background for this study is rooted in the need to understand the potential health implications of cannabis use disorder (CUD), especially in relation to cardiovascular health.

Cannabis has become increasingly popular for both recreational and medicinal purposes, and it is essential to assess its impact on various health outcomes.

Continue reading

Study Assesses Quality of Life After Cannabis Prescribed for Chronic Pain and Other Health Symptoms

PainRelief.com Interview with:
Margaret-Ann Tait | PhD candidate
Project Manager, The QUEST Initiative
Research Manager, Faculty of Medicine and Health
Sydney Nursing School, Cancer Care Research Unit
University of Sydney

PainRelief.com: What is the background for this study?

Response: In 2016 Australia passed legislation that allows cannabis use for medicinal purposes. Since then, an estimated 800,000 patients have received medicinal cannabis prescriptions. We wanted to know if patients with chronic health conditions in Australia are reporting their health outcomes differently after being prescribed medicinal cannabis. We used validated questionnaires to assess their health-related quality of life, levels of fatigue, pain, sleep disturbance, anxiety, and depression before starting therapy and then at regular intervals for three months after. 

We had 2327 patients participating from across Australia aged between 18 and 97 (the average age was 51), and nearly two thirds were female. Half of our participants were prescribed medicinal cannabis for more than one condition, with chronic pain conditions reported more frequently, followed by insomnia, anxiety, and mixed anxiety & depression.

Continue reading

Patients Report Substituting Cannabis for Pain Relief Medications

PainRelief.com Interview with:
Mark Christopher Bicket, MD, PhD
Assistant Professor,Department of Anesthesiology
Assistant Professor,Health Management and Policy
School of Public Health
University of MichiganAnn Arbor, MI 48109

PainRelief.com: What is the background for this study? What are the main findings?

  • Most states have laws that allow people with chronic pain to use cannabis as a treatment. But evidence about whether medical cannabis use lowers the use of other treatments for chronic pain is not clear. 
  • We conducted a rigorous survey of adults living in the 36 states and D.C. in the spring of 2022.
  • Among the 1,661 adults who had chronic pain, we asked about their use of cannabis, prescription opioids, and non-opioid treatments for chronic pain. 
  • Cannabis use for chronic pain was common, reported in roughly 3 in 10 people at any time and 1 in 4 in the past year.
  • In contrast, a minority said cannabis use decreased their use of non-pharmacologic treatments like physical therapy or meditation, and some reported their use increased.

Use of Medical Cannabis Can Expose Patients to Harmful Contaminants

PainRelief.com Interview with:
Maxwell C. K. Leung, Ph.D.
Assistant Professor
Systems Biology and Toxicology
New College of Interdisciplinary Arts and Sciences
Arizona State University, West Campus

PainRelief.com: What is the background for this study?

Response: Over 200 million Americans currently have legal access to medical cannabis, recreational cannabis, or both. Yet, cannabis remains an illicit Schedule 1 substance at the federal level. This limits the efforts of several federal agencies to regulate harmful contaminants – including pesticides, heavy metals, solvents, microbes, and fungal toxins – in cannabis.

Cannabis During Pregnancy May Have Long Term Mental Health Consequences for Children

David-Baranger
Dr. Baranger

PainRelief.com Interview with:

David A. A. Baranger, PhD
Department of Psychological and Brain Sciences

Dr. Brogdan

Ryan Bogdan, PhD
Associate Professor of Psychological & Brain Sciences
Department of Psychiatry
Washington University in St Louis
St Louis, Missouri



PainRelief.com: What is the background for this study? What are the main findings?

David Baranger: Prenatal cannabis use is increasing in the United States. Prior work from our group found that prenatal cannabis exposure, particularly when it occurred after mothers learned they were pregnant, was associated with worse mental health outcomes in children aged 9-10.

In this study we followed up with this same group of children, who are now as old as 12, to ask whether anything has changed. Have they improved, or gotten worse? To our surprise, we found that children with prenatal cannabis exposure still had worse mental health outcomes – things had not gotten better, nor had they gotten worse.  

Drug Stocks Drop When Recreational Cannabis Legalized

PainRelief.com Interview with:

Sarah Stith PhD
Assistant Professor of Economics
University of New Mexico

Dr. Stith

PainRelief.com: What is the background for this study?

Response: We studied how the stock market returns of publicly traded pharmaceutical firms responded to medical and recreational cannabis legalization events. Our results show that stock market returns were 1.5-2% lower at 10 days following a single cannabis legalization event and that the annual sales implications from this reduction were in the billions.

Twin Study Find Cannabis Legalization Linked to Increased Marijuana Use in Adults

PainRelief.com Interview with:
Stephanie Zellers
Psychology
University of Minnesota

PainRelief.com: What is the background for this study?

Response: Many cross-sectional studies have found increases in adult cannabis consumption after the passage of recreational cannabis legalization. These studies, in large population samples across the USA, provide information about possible effects of recreational legalization in representative samples, but cannot draw causally informative conclusions. There are many confounders, like genes, pre-existing differences, and secular trends, that could be alternative explanations for any effects identified.

We utilized a longitudinal twin study to rule out many additional unmeasured confounds shared within families, like genes and aspects of the rearing environment. Importantly, we have data on identical twins before and after recreational legalization, and we have pairs where one twin lives in a recreationally legal state while their co-twin does not. By comparing these twins, we can estimate the causal impact of recreational legalization, after controlling for unmeasured confounds shared by individuals in a family.